Ipsen outlined some promising mid-term takeaways at the CMD
08/12/23 -"Ipsen has unveiled its mid-term plan, with healthy sales growth and profitability improvements despite Somatuline generics erosion (the lynchpin offering). These developments are likely to be ..."
Pages
55
Language
English
Published on
08/12/23
You may also be interested by these reports :
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...
06/05/25
1:10 share split adjustments – Downgrade to Add (prev.: Buy)
06/05/25
Q1 results met expectations, and strong growth was witnessed across the segments as well as three key molecules. Of note was a rebound in the animal ...
05/05/25
BioNTech’s narrative is straightforward: the company develops drugs for life-threatening illnesses and generated significant revenue by developing ...